Self-Management Interventions After an ICD Shock
Biobehavioral Intervention to Reduce PTSD After ICD Shock
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Cynthia M Dougherty, ARNP, PhD
- Phone Number: 206 221-7927
- Email: cindyd@uw.edu
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98195
- Recruiting
- University of Washington
-
Contact:
- Cynthia Dougherty, ARNP, PhD
- Phone Number: 206-221-7927
- Email: cindyd@u.washington.edu
-
Principal Investigator:
- Cynthia Dougherty, ARNP, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ICD implant for primary or secondary prevention of sudden cardiac arrest (SCA),
- receipt of at least 1 ICD shock, appropriate or inappropriate, one week prior to enrollment;
- able to read, speak and write English;
- access to online resources and telephone for study duration.
Exclusion Criteria:
- current diagnosis of PTSD, schizophrenia or bipolar disorder;
- Short BLESSED score >6 indicating cognitive dysfunction [73];
- age <18 years;
- AUDIT-C score ≥4 for alcohol use;
- regular non-medical use of illicit drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SPSM intervention
Heart rate self monitoring Online shock management modules
|
(SPSM) consists of two components: 1) HR Self-monitoring, and 2) online Shock Management modules (N=4) with weekly telephone coaching, completed over 1 month.
|
|
No Intervention: usual care
standard observation and post-ICD shock care at each clinic that includes ICD interrogations monitored in-person or via home monitor
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ICD Shock anxiety
Time Frame: Baseline, 1, 6 months
|
Florida Shock Anxiety Scale: range 1-50, higher is higher anxiety.
|
Baseline, 1, 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total daily physical activity(steps/day)
Time Frame: Baseline, 1, 6 months
|
Step Watch Activity Monitor, 0-unlimited number of steps.
Higher is more steps.
|
Baseline, 1, 6 months
|
|
Depression
Time Frame: Baseline, 1, 6 months
|
PHQ-9, 0-27.
Higher is higher depression.
|
Baseline, 1, 6 months
|
|
PTSD Symptoms
Time Frame: Baseline, 1, 6 months
|
Post-traumatic Stress Disorder Checklist PCL-5, 0-80.
Higher is higher PTSD symtpoms
|
Baseline, 1, 6 months
|
|
Quality of Life-Physical and Mental
Time Frame: Baseline, 1, 6 months
|
PROMIS Global v 2.0, 0-50.
Higher is higher qol.
|
Baseline, 1, 6 months
|
|
Outcome expectation, 0-90. Higher is higher OE.
Time Frame: Baseline, 1, 6 months
|
OE Scale
|
Baseline, 1, 6 months
|
|
Salivary cortisol
Time Frame: Baseline, 1, 6 months
|
Cortisol in saliva, the range in humans varies.
measured in pg/ml.
|
Baseline, 1, 6 months
|
|
Acceptability
Time Frame: 6 months
|
Acceptability of interventions and materials measured in terms of patient burden (time to complete questionnaires & data collection, ease in understanding, implementing the intervention).
These are qualitative open ended answers to questions and do not produce a number.
|
6 months
|
|
Self-Efficacy Expectations
Time Frame: Baseline, 1, 6 months
|
Self-Efficacy Expectations-SE scale, 0-60, Higher is more self-efficacy
|
Baseline, 1, 6 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of implementing the intervention (composite outcome)
Time Frame: 6 months
|
Feasibility will be measured using patient recruitment and contact rates (reach within 1-3 days of shock, number screened, eligible & enrolled, proportion eligible vs agree to participate).
Each of these variables creates a number for the total study.
They elements are added together to get a score.
|
6 months
|
|
Safety (composite outcome) of the intervention
Time Frame: 2 years of the trial
|
Safety: major adverse cardiac events, including mortality (all cause and cardiac).
This is measured as yes or no.
Each outcome is score and the total number is summarized.
|
2 years of the trial
|
|
Acceptability of the intervention (composite outcome)
Time Frame: 6 months
|
Acceptability of interventions and materials measured in terms of patient burden (time to complete questionnaires & data collection, ease in understanding, implementing the intervention).
These are qualitative open ended answers to questions and do not produce a number.
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Cynthia M Dougherty, ARNP, PhD, University of Washington
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- STUDY00007840
- 1R21NR020967-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.